Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125746681 | 12574668 | 1 | I | 20160711 | 20160720 | 20160720 | EXP | GB-MHRA-EYC 00142031 | GB-PFIZER INC-2016339428 | PFIZER | 83.00 | YR | M | Y | 0.00000 | 20160720 | PH | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125746681 | 12574668 | 1 | PS | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Oral | 25 MG, 1X/DAY | Y | 12151 | 25 | MG | QD | ||||||
| 125746681 | 12574668 | 2 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | UNK | 0 | ||||||||||
| 125746681 | 12574668 | 3 | C | BISOPROLOL | BISOPROLOL | 1 | Oral | UNK | 0 | ||||||||||
| 125746681 | 12574668 | 4 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | UNK | 0 | ||||||||||
| 125746681 | 12574668 | 5 | C | RAMIPRIL. | RAMIPRIL | 1 | Oral | UNK | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125746681 | 12574668 | LT |
| 125746681 | 12574668 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125746681 | 12574668 | Hyperkalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |